Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Navidea Biopharmaceuticals Inc    NAVB

 SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
12/01/2016 12/02/2016 12/05/2016 12/06/2016 12/07/2016 Date
0.7231(c) 0.71(c) 0.7351(c) 0.7366(c) 0.73 Last
1 890 120 893 399 672 924 470 209 273 388 Volume
-8.75% -1.81% +3.54% +0.20% -0.90% Change
More quotes
Financials ($)
More Financials
Company
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutic.It is developing multiple precision-targeted products based on their manocept platform to help identify the sites and... 
More about the company
Latest news on NAVIDEA BIOPHARMACEUTICALS
12/01 NAVIDEA BIOPHARMACEUTICALS : Signs Asset Purchase Agreement with Cardinal Health
11/30 NAVIDEA BIOPHARMACEUTICALS, INC. (NY : NAVB) Files An 8-K Entry into a Material ..
11/30 NAVIDEA BIOPHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, F..
11/23 NAVIDEA BIOPHARMACEUTICALS : Signs Asset Purchase Agreement with Cardinal Health
11/10 Navidea Reports 2016 Third Quarter Financial Results
11/09 NAVIDEA BIOPHARMACEUTICALS : Management's Discussion and Analysis of Financial C..
11/03 NAVIDEA BIOPHARMACEUTICALS : to Announce Third Quarter 2016 Financial Results on..
11/03 NAVIDEA BIOPHARMACEUTICALS (NYSEMKT : NAVB) Files An 8-K Reports 2016 Third Quar..
11/03 NAVIDEA BIOPHARMACEUTICALS, INC. : Results of Operations and Financial Condition..
11/03 NAVIDEA BIOPHARMACEUTICALS : posts 3Q loss
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
11/23 Navidea sells Lymphoseek to Cardinal Health for up to $310M; shares up 5%
11/23 Trading in Navidea halted pending news
11/03 Navidea Biopharmaceuticals' (NAVB) CEO Michael Goldberg on Q3 2016 Results - ..
11/03 Navidea Biopharm net loss improves in Q3
11/03 Navidea Biopharm beats by $0.02, beats on revenue
Advertisement
Chart NAVIDEA BIOPHARMACEUTICALS
Duration : Period :
Navidea Biopharmaceuticals Technical Analysis Chart | NAVB | US63937X1037 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target -100%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mike M. Goldberg President, Chief Executive Officer & Director
Eric K. Rowinsky Chairman
Jed Andrew Latkin Chief Operating & Financial Officer
Frederick O. Cope Chief Scientific Officer & Senior Vice President
Michael Tomblyn Chief Medical Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NAVIDEA BIOPHARMACEUTI..-46.62%115
INCYTE CORPORATION-1.14%20 197
QUINTILES IMS HOLDINGS..12.99%19 099
CELLTRION, INC.--.--%9 992
SEATTLE GENETICS, INC.48.48%9 433
LONZA GROUP AG8.34%9 288
More Results